FDA Approves Tissue-Based Companion Diagnostic for PIK3CA-Mutated Breast Cancer
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
Read MorePosted by CLP Edit Staff | Jun 3, 2026 | Breast |
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
Read MorePosted by CLP Edit Staff | Jun 2, 2026 | Cancer, Molecular Diagnostics |
Clinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MorePosted by CLP Edit Staff | Jun 1, 2026 | Prostate |
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read MorePosted by CLP Edit Staff | Jun 1, 2026 | Cancer, Diagnostic Technologies, Molecular Diagnostics |
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MorePosted by CLP Edit Staff | May 29, 2026 | Compliance, Lung Cancer |
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read More